HRF II - Hamburger Rheuma Forschungszentrum II MVZ für Rheumatologie und Autoimmunmedizin Hamburg GmbH
Welcome,         Profile    Billing    Logout  
 1 Trial 
19 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
AVOUAC, Jérôme
SUNSTAR, NCT03227419 / 2017-000947-41: Abatacept vs Tocilizumab for the Treatment of RA in TNF Alpha Inhibitor Inadequate Responders

Recruiting
4
224
Europe
Tocilizumab Prefilled Syringe, RoActemra, Abatacept Prefilled Syringe, Orencia
Lille Catholic University
Arthritis, Rheumatoid
09/24
11/24
SEQUENS-RA, NCT05428488: Efficacy of a Sequential Treatment Strategy in Rheumatoid Arthritis

Recruiting
3
220
Europe, RoW
Abatacept (W12-W48), TNF Inhibitor (W12-W48), TNF Inhibitor (W0-W12)
University Hospital, Montpellier
Rheumatoid Arthritis
11/26
11/27
CRI-RA, NCT04870203: Combination of Baricitinib and Anti-TNF in Rheumatoid Arthritis

Recruiting
3
178
Europe, RoW
baricitinib treatment, anti-TNF therapy, Placebo
University Hospital, Bordeaux, Eli Lilly and Company, Biogen, Ministry for Health and Solidarity, France
Rheumatoid Arthritis
12/26
12/26
NCT05848258: An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis

Recruiting
2
380
Europe, US, RoW
LY3871801, Placebo
Eli Lilly and Company, Rigel Pharmaceuticals
Rheumatoid Arthritis
02/26
07/26
ePRAT, NCT05124782: Virtual Management of Rheumatoid Arthritis

Recruiting
N/A
100
Europe
Rheumatoid Arthritis Impact of Disease questionnaire
Assistance Publique - Hôpitaux de Paris
Rheumatoid Arthritis
11/23
03/24
SAPHIR, NCT05598684: : Assessment of Predictive Factors for Persistence of Treatment After Initiation of Adalimumab With a Biosimilar (Adalimumab Fresenius KaBI or Substitution of Reference Adalimumab With the Fresenius Kabi Adalimumab Biosimilar in Patients With Chronic Inflammatory Diseases

Recruiting
N/A
600
Europe, RoW
Fresenius Kabi, France
Crohn Disease, Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis
09/25
12/25
SIC2, NCT05424926: Sub-cutaneous Infliximab in Inflammatory Rheumatic Disease

Active, not recruiting
N/A
22
Europe
collection of clinical parameters and blood sample
Assistance Publique - Hôpitaux de Paris
Rheumatoid Arthritis, Spondyloarthritis, Psoriatic Arthritis
12/23
02/25
Neeck, Gunther
NCT04314544: Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)

Active, not recruiting
3
510
Europe, Canada, US, RoW
TILD, matching placebo injections
Sun Pharmaceutical Industries Limited
Active Psoriatic Arthritis
09/25
05/26
LATITUDE-PsA-3001, NCT06671483: A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines

Recruiting
3
1088
Europe, US, RoW
Zasocitinib, TAK- 279, NDI-034858, Active Comparator, Placebo
Takeda
Psoriatic Arthritis
05/27
01/28
NCT05848258: An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis

Recruiting
2
380
Europe, US, RoW
LY3871801, Placebo
Eli Lilly and Company, Rigel Pharmaceuticals
Rheumatoid Arthritis
02/26
07/26
Everding, Andrea
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting
3
16700
Europe, Canada, Japan, US, RoW
Lepodisiran Sodium, LY3819469, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
03/29
03/29
ARGX-113-2306, NCT06684847: A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome

Recruiting
3
580
Europe, Canada, Japan, US, RoW
Efgartigimod PH20 SC, Placebo PH20 SC
argenx
Primary Sjogrens Disease
07/27
07/28
LATITUDE-PsA-3001, NCT06671483: A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines

Recruiting
3
1088
Europe, US, RoW
Zasocitinib, TAK- 279, NDI-034858, Active Comparator, Placebo
Takeda
Psoriatic Arthritis
05/27
01/28
LATITUDE-PsA-3002, NCT06671496: A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines

Recruiting
3
600
Europe, Canada, Japan, US, RoW
Zasocitinib, TAK- 279, NDI-034858, Placebo
Takeda
Psoriatic Arthritis
05/27
01/28
NCT05436652 / 2022-000299-20: A Trial of Prednisolone in Combination With SPI-62 or Placebo in Subjects With Polymyalgia Rheumatica (PMR)

Completed
2
66
Europe
SPI-62, SPI-62 matched placebo, Prednisolone 10mg, Additional prednisolone, Additional prednisolone matched placebo
Sparrow Pharmaceuticals
Polymyalgia Rheumatica
04/25
04/25
NCT05848258: An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis

Recruiting
2
380
Europe, US, RoW
LY3871801, Placebo
Eli Lilly and Company, Rigel Pharmaceuticals
Rheumatoid Arthritis
02/26
07/26
MARS-17, NCT05838742: A Dose-Finding Study to Evaluate the Efficacy and Safety of GSK3858279 in Adults With Knee Osteoarthritis (OA) Pain

Terminated
2
314
Europe, Canada, Japan, US, RoW
GSK3858279, Placebo
GlaxoSmithKline
Pain, Osteoarthritis, Knee
08/24
12/24
VARIN, Stéphane
ROC-SPA, NCT03445845: Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis

Completed
4
300
Europe, RoW
Secukinumab, TNF blocker, blood specimen
Centre Hospitalier Universitaire de Saint Etienne, Ministry of Health, France
Axial Spondyloarthritis
09/24
10/24
NCT05848258: An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis

Recruiting
2
380
Europe, US, RoW
LY3871801, Placebo
Eli Lilly and Company, Rigel Pharmaceuticals
Rheumatoid Arthritis
02/26
07/26
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
AVOUAC, Jérôme
SUNSTAR, NCT03227419 / 2017-000947-41: Abatacept vs Tocilizumab for the Treatment of RA in TNF Alpha Inhibitor Inadequate Responders

Recruiting
4
224
Europe
Tocilizumab Prefilled Syringe, RoActemra, Abatacept Prefilled Syringe, Orencia
Lille Catholic University
Arthritis, Rheumatoid
09/24
11/24
SEQUENS-RA, NCT05428488: Efficacy of a Sequential Treatment Strategy in Rheumatoid Arthritis

Recruiting
3
220
Europe, RoW
Abatacept (W12-W48), TNF Inhibitor (W12-W48), TNF Inhibitor (W0-W12)
University Hospital, Montpellier
Rheumatoid Arthritis
11/26
11/27
CRI-RA, NCT04870203: Combination of Baricitinib and Anti-TNF in Rheumatoid Arthritis

Recruiting
3
178
Europe, RoW
baricitinib treatment, anti-TNF therapy, Placebo
University Hospital, Bordeaux, Eli Lilly and Company, Biogen, Ministry for Health and Solidarity, France
Rheumatoid Arthritis
12/26
12/26
NCT05848258: An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis

Recruiting
2
380
Europe, US, RoW
LY3871801, Placebo
Eli Lilly and Company, Rigel Pharmaceuticals
Rheumatoid Arthritis
02/26
07/26
ePRAT, NCT05124782: Virtual Management of Rheumatoid Arthritis

Recruiting
N/A
100
Europe
Rheumatoid Arthritis Impact of Disease questionnaire
Assistance Publique - Hôpitaux de Paris
Rheumatoid Arthritis
11/23
03/24
SAPHIR, NCT05598684: : Assessment of Predictive Factors for Persistence of Treatment After Initiation of Adalimumab With a Biosimilar (Adalimumab Fresenius KaBI or Substitution of Reference Adalimumab With the Fresenius Kabi Adalimumab Biosimilar in Patients With Chronic Inflammatory Diseases

Recruiting
N/A
600
Europe, RoW
Fresenius Kabi, France
Crohn Disease, Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis
09/25
12/25
SIC2, NCT05424926: Sub-cutaneous Infliximab in Inflammatory Rheumatic Disease

Active, not recruiting
N/A
22
Europe
collection of clinical parameters and blood sample
Assistance Publique - Hôpitaux de Paris
Rheumatoid Arthritis, Spondyloarthritis, Psoriatic Arthritis
12/23
02/25
Neeck, Gunther
NCT04314544: Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)

Active, not recruiting
3
510
Europe, Canada, US, RoW
TILD, matching placebo injections
Sun Pharmaceutical Industries Limited
Active Psoriatic Arthritis
09/25
05/26
LATITUDE-PsA-3001, NCT06671483: A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines

Recruiting
3
1088
Europe, US, RoW
Zasocitinib, TAK- 279, NDI-034858, Active Comparator, Placebo
Takeda
Psoriatic Arthritis
05/27
01/28
NCT05848258: An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis

Recruiting
2
380
Europe, US, RoW
LY3871801, Placebo
Eli Lilly and Company, Rigel Pharmaceuticals
Rheumatoid Arthritis
02/26
07/26
Everding, Andrea
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting
3
16700
Europe, Canada, Japan, US, RoW
Lepodisiran Sodium, LY3819469, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
03/29
03/29
ARGX-113-2306, NCT06684847: A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome

Recruiting
3
580
Europe, Canada, Japan, US, RoW
Efgartigimod PH20 SC, Placebo PH20 SC
argenx
Primary Sjogrens Disease
07/27
07/28
LATITUDE-PsA-3001, NCT06671483: A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines

Recruiting
3
1088
Europe, US, RoW
Zasocitinib, TAK- 279, NDI-034858, Active Comparator, Placebo
Takeda
Psoriatic Arthritis
05/27
01/28
LATITUDE-PsA-3002, NCT06671496: A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines

Recruiting
3
600
Europe, Canada, Japan, US, RoW
Zasocitinib, TAK- 279, NDI-034858, Placebo
Takeda
Psoriatic Arthritis
05/27
01/28
NCT05436652 / 2022-000299-20: A Trial of Prednisolone in Combination With SPI-62 or Placebo in Subjects With Polymyalgia Rheumatica (PMR)

Completed
2
66
Europe
SPI-62, SPI-62 matched placebo, Prednisolone 10mg, Additional prednisolone, Additional prednisolone matched placebo
Sparrow Pharmaceuticals
Polymyalgia Rheumatica
04/25
04/25
NCT05848258: An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis

Recruiting
2
380
Europe, US, RoW
LY3871801, Placebo
Eli Lilly and Company, Rigel Pharmaceuticals
Rheumatoid Arthritis
02/26
07/26
MARS-17, NCT05838742: A Dose-Finding Study to Evaluate the Efficacy and Safety of GSK3858279 in Adults With Knee Osteoarthritis (OA) Pain

Terminated
2
314
Europe, Canada, Japan, US, RoW
GSK3858279, Placebo
GlaxoSmithKline
Pain, Osteoarthritis, Knee
08/24
12/24
VARIN, Stéphane
ROC-SPA, NCT03445845: Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis

Completed
4
300
Europe, RoW
Secukinumab, TNF blocker, blood specimen
Centre Hospitalier Universitaire de Saint Etienne, Ministry of Health, France
Axial Spondyloarthritis
09/24
10/24
NCT05848258: An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis

Recruiting
2
380
Europe, US, RoW
LY3871801, Placebo
Eli Lilly and Company, Rigel Pharmaceuticals
Rheumatoid Arthritis
02/26
07/26

Download Options